Finance

Lister
WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
12,56 USD
+0,48%
(+0,060) 1 D
16. okt., 16:00:00 GMT-4  ·   USD
Alle symboler
SymbolPrisEndringEndring (%)
Genererer viktig statistikk for WXXWY …
Åpne
12,29 USD
Høy
12,56 USD
Lav
12,20 USD
Markedsverdi
198,43 mrd.
Snittvolum
61,89k
Volum
110,85k
52 u høy
14,80 USD
52 u lav
7,30 USD
Beta
0,01
Utestående aksjer
2,06 mrd.
Antall ansatte
15k
Åpne
12,29 USD
Høy
12,56 USD
Lav
12,20 USD
Markedsverdi
198,43 mrd.
Snittvolum
61,89k
Volum
110,85k
52 u høy
14,80 USD
52 u lav
7,30 USD
Beta
0,01
Utestående aksjer
2,06 mrd.
Antall ansatte
15k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Om Wuxi Biologics Cayman ADR
Administrerende direktørZhisheng Chen
Ansatte14,7k
Grunnlagt2010
Hovedkontor-
Sektor-
Nettstedwuxibiologics.com
Tidligere rapporterAlle verdier i CNY
Loading Previous Earnings...
Inntekt
Nettoinntekt
Alle verdier i CNY
sep. 2025
des. 2025
mars 2026
juni 2026
Inntekt
5,92 mrd.
5,92 mrd.
5,89 mrd.
5,89 mrd.
Varekostnad
3,04 mrd.
3,04 mrd.
3,17 mrd.
3,17 mrd.
Direkte driftskostnader
3,04 mrd.
3,04 mrd.
3,17 mrd.
3,17 mrd.
Utgifter til forskning og utvikling
254,93 mill.
254,93 mill.
215,11 mill.
215,11 mill.
Totale kostnader til forskning og utvikling
-
-
-
-
Salgskostnader, generelle kostnader og administrative kostnader
631,03 mill.
631,03 mill.
591,61 mill.
591,61 mill.
Driftskostnader
921,71 mill.
921,71 mill.
860,09 mill.
860,09 mill.
Totale driftskostnader
3,96 mrd.
3,96 mrd.
4,03 mrd.
4,03 mrd.
Driftsinntekter
1,96 mrd.
1,96 mrd.
1,86 mrd.
1,86 mrd.
Andre ikke-operasjonelle inntekter
33,58 mill.
33,58 mill.
42,20 mill.
42,20 mill.
EBT inkludert uvanlige elementer
1,96 mrd.
1,96 mrd.
1,71 mrd.
1,71 mrd.
EBT uten uvanlige elementer
1,94 mrd.
1,94 mrd.
1,70 mrd.
1,70 mrd.
Kostnad for inntektsskatt
476,10 mill.
476,10 mill.
251,54 mill.
251,54 mill.
Faktisk avgiftssats
24,24 %
24,24 %
14,71 %
14,71 %
Andre driftskostnader
-
-
-
-
Nettoinntekt
1,28 mrd.
1,28 mrd.
1,22 mrd.
1,22 mrd.
Netto fortjenestemargin
21,70 %
21,70 %
20,70 %
20,70 %
Resultat per aksje
-
-
-
-
Rente- og investeringsinntekter
115,29 mill.
115,29 mill.
106,38 mill.
106,38 mill.
Rentekostnader
−29,76 mill.
−29,76 mill.
−22,28 mill.
−22,28 mill.
Netto rentekostnader
85,53 mill.
85,53 mill.
84,10 mill.
84,10 mill.
Avskrivnings- og amortiseringskostnader
-
-
-
-
EBITDA
2,24 mrd.
2,24 mrd.
2,27 mrd.
2,27 mrd.
Gevinst eller tap ved salg av eiendeler
317,34 mill.
317,34 mill.
-
-
AI-innhold kan inneholde feil. Finn ut mer
HjelpSend tilbakemeldingPersonvernVilkårAnsvarsfraskrivelse
Google-apper